116 related articles for article (PubMed ID: 38644292)
21. Increasing of FKBP9 can predict poor prognosis in patients with prostate cancer.
Jiang FN; Dai LJ; Yang SB; Wu YD; Liang YX; Yin XL; Zou CY; Zhong WD
Pathol Res Pract; 2020 Jan; 216(1):152732. PubMed ID: 31780055
[TBL] [Abstract][Full Text] [Related]
22. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
[TBL] [Abstract][Full Text] [Related]
23. A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.
Rade M; Kreuz M; Borkowetz A; Sommer U; Blumert C; Füssel S; Bertram C; Löffler D; Otto DJ; Wöller LA; Schimmelpfennig C; Köhl U; Gottschling AC; Hönscheid P; Baretton GB; Wirth M; Thomas C; Horn F; Reiche K
Mol Med; 2024 Feb; 30(1):19. PubMed ID: 38302875
[TBL] [Abstract][Full Text] [Related]
24. A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence.
Xing Q; Liu S; Luan J; Wang Y; Ma L
Pathol Res Pract; 2021 Sep; 225():153587. PubMed ID: 34419719
[TBL] [Abstract][Full Text] [Related]
25. Lipid metabolism-related miRNAs with potential diagnostic roles in prostate cancer.
Zhai T; Dou M; Ma Y; Wang H; Liu F; Zhang L; Chong T; Wang Z; Xue L
Lipids Health Dis; 2023 Mar; 22(1):39. PubMed ID: 36915125
[TBL] [Abstract][Full Text] [Related]
26. SOXs in human prostate cancer: implication as progression and prognosis factors.
Zhong WD; Qin GQ; Dai QS; Han ZD; Chen SM; Ling XH; Fu X; Cai C; Chen JH; Chen XB; Lin ZY; Deng YH; Wu SL; He HC; Wu CL
BMC Cancer; 2012 Jun; 12():248. PubMed ID: 22703285
[TBL] [Abstract][Full Text] [Related]
27. Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7.
Tirode F; Busso D; Coin F; Egly JM
Mol Cell; 1999 Jan; 3(1):87-95. PubMed ID: 10024882
[TBL] [Abstract][Full Text] [Related]
28. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.
de Resende MF; Vieira S; Chinen LT; Chiappelli F; da Fonseca FP; Guimarães GC; Soares FA; Neves I; Pagotty S; Pellionisz PA; Barkhordarian A; Brant X; Rocha RM
J Transl Med; 2013 Feb; 11():36. PubMed ID: 23398928
[TBL] [Abstract][Full Text] [Related]
29. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
[TBL] [Abstract][Full Text] [Related]
30. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
Sun X; Liu Z; Yang Z; Xiao L; Wang F; He Y; Su P; Wang J; Jing B
Diagn Pathol; 2013 Dec; 8():208. PubMed ID: 24350576
[TBL] [Abstract][Full Text] [Related]
31. RNA polymerase II elongation complexes containing the Cockayne syndrome group B protein interact with a molecular complex containing the transcription factor IIH components xeroderma pigmentosum B and p62.
Tantin D
J Biol Chem; 1998 Oct; 273(43):27794-9. PubMed ID: 9774388
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylation of XPB helicase regulates TFIIH nucleotide excision repair activity.
Coin F; Auriol J; Tapias A; Clivio P; Vermeulen W; Egly JM
EMBO J; 2004 Dec; 23(24):4835-46. PubMed ID: 15549133
[TBL] [Abstract][Full Text] [Related]
33. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence.
Huang JB; Wu YP; Lin YZ; Cai H; Chen SH; Sun XL; Li XD; Wei Y; Zheng QS; Xu N; Xue XY
J Cell Mol Med; 2020 Apr; 24(8):4698-4706. PubMed ID: 32168432
[TBL] [Abstract][Full Text] [Related]
35. The relationship between homeobox B7 expression and the clinical characteristics of patient with prostate cancer.
Song Z; Liao Z; Cui Y; Yang C
J Cell Biochem; 2019 Apr; 120(4):6395-6401. PubMed ID: 30317675
[TBL] [Abstract][Full Text] [Related]
36. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
37. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model.
Diallo JS; Aldejmah A; Mouhim AF; Péant B; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2007 Dec; 13(23):7044-52. PubMed ID: 18056181
[TBL] [Abstract][Full Text] [Related]
38. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.
Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R
BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850
[TBL] [Abstract][Full Text] [Related]
39. The established chemokine-related prognostic gene signature in prostate cancer: Implications for anti-androgen and immunotherapies.
Chen L; Zheng Y; Jiang C; Yang C; Zhang L; Liang C
Front Immunol; 2022; 13():1009634. PubMed ID: 36275733
[TBL] [Abstract][Full Text] [Related]
40. FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.
Pecqueux C; Arslan A; Heller M; Falkenstein M; Kaczorowski A; Tolstov Y; Sültmann H; Grüllich C; Herpel E; Duensing A; Kristiansen G; Hohenfellner M; Navone NM; Duensing S
Urol Oncol; 2018 Aug; 36(8):365.e15-365.e26. PubMed ID: 29887238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
